Nakashima J, Sumitomo M, Miyajima A, Jitsukawa S, Murai M
Department of Urology, Urawa Municipal Hospital, Japan.
Urol Int. 1997;58(4):236-8. doi: 10.1159/000282991.
Procollagen 1 carboxyterminal peptide (P1CP) is thought to be an indicator of new bone formation. The present report demonstrates that effective endocrine therapy induced an initial increase followed by a delayed decrease in serum levels of P1CP and alkaline phosphatase in spite of an immediate decrease in serum PSA and PAP and improvement of clinical symptoms in prostate cancer patients with bone metastases. The transient increase in P1CP and alkaline phosphatase is a healing reaction and is followed by apparent improvement. Short-term effects of endocrine therapy on prostate cancer patients with bone metastases should be comprehensively evaluated based upon the entire spectrum of clinical and laboratory findings including serial changes of serum prostate markers and bone markers as well.
前胶原1羧基末端肽（P1CP）被认为是新骨形成的一个指标。本报告表明，尽管前列腺癌骨转移患者的血清前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）立即下降且临床症状有所改善，但有效的内分泌治疗导致血清P1CP和碱性磷酸酶水平先出现初始升高，随后延迟下降。P1CP和碱性磷酸酶的短暂升高是一种愈合反应，随后会有明显改善。对于前列腺癌骨转移患者，应基于包括血清前列腺标志物和骨标志物的系列变化在内的临床和实验室检查结果的全谱，全面评估内分泌治疗的短期效果。
